Maintenance outage: This site will be inaccessible from late evening Mar 7th thru Mar 8th. This is for scheduled technology upgrades by our global hosting service that are affecting numerous websites and online journals. Note that our submission site is still accessible during this period and processing of new submissions will not be affected.
Article Information
History
- August 22, 2024.
Article Versions
- You are currently viewing Version 1 of this article (August 22, 2024 - 09:31).
- Version 2 (August 26, 2024 - 05:38).
- Version 3 (August 26, 2024 - 13:42).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Girish Harinath1,2,
- Virginia Lee1,2,
- Andy Nyquist1,
- Mauricio Moel1,
- Jesper Hagemeier1,
- Stefanie L. Morgan1,2,*,
- Anar Isman1 and
- Sajad Zalzala1
- 1AgelessRx, Ann Arbor MI, USA
- 2Division of Research and Applied Sciences, AgelessRx, Ann Arbor MI, USA
- 3Data and Analytics Division, AgelessRx, Ann Arbor MI, USA
- ↵*Corresponding author
: Stefanie L Morgan, stefanie{at}agelessrx.com
Posted August 22, 2024.
Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
9
Blogs/Media
Author Videos